Generates economic returns by investing in and holding equity/SAFE interests in digital-health and medical R&D companies, seeking value uplift and exit events.
Geographic Exposure
United States75%
Europe25%
Revenue Drivers
Fair value gains on investments
Recognizes gains from revaluing portfolio equity and SAFE investments.
CORE100%
End Markets
Institutional investors
Public market investors (limited partners)
Early-stage and growth-stage health technology companies (as investment targets)
Specializations
Digital health R&D investingMedical device and wearable monitoring investmentsGenomics and AI diagnostics investmentsComputational drug design investmentsHealthcare cybersecurity investmentsData privacy and security compliance awareness (HIPAA/GDPR concepts)
